178 related articles for article (PubMed ID: 15379382)
1. Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):135-56. PubMed ID: 15379382
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
3. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938
[TBL] [Abstract][Full Text] [Related]
4. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
6. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
7. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
Hassan M; Svensson US; Ljungman P; Björkstrand B; Olsson H; Bielenstein M; Abdel-Rehim M; Nilsson C; Johansson M; Karlsson MO
Br J Clin Pharmacol; 1999 Nov; 48(5):669-77. PubMed ID: 10594468
[TBL] [Abstract][Full Text] [Related]
8. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
Huang L; Winger BA; Cheah V; Gingrich D; Marzan F; Lu Y; Cooper JC; Aweeka F; Long-Boyle J
J Chromatogr Open; 2022 Nov; 2():. PubMed ID: 35875822
[TBL] [Abstract][Full Text] [Related]
9. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
11. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Br J Clin Pharmacol; 2001 Jan; 51(1):61-70. PubMed ID: 11167666
[TBL] [Abstract][Full Text] [Related]
13. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
[TBL] [Abstract][Full Text] [Related]
14. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
15. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2005 Mar; 16(3):331-6. PubMed ID: 15711186
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
de Jonge ME; van Dam SM; Hillebrand MJ; Rosing H; Huitema AD; Rodenhuis S; Beijnen JH
J Mass Spectrom; 2004 Mar; 39(3):262-71. PubMed ID: 15039933
[TBL] [Abstract][Full Text] [Related]
18. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.
Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J
Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958
[TBL] [Abstract][Full Text] [Related]
20. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
de Jonge ME; Huitema AD; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 May; 55(5):507-10. PubMed ID: 15685452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
